A novel method for repositioning an FDA-approved anti-cancer compound has been discovered, which allows it to specifically target liver cancer tumors. A ‘triple attack’ technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.